Atossa Therapeutics (NASDAQ:ATOS) just reported results for the fourth quarter of 2023.
- Atossa Therapeutics reported earnings per share of -6 cents. This was below the analyst estimate for EPS of -5 cents.
- The company did not report any revenue for the quarter.